Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC

A large real‑world study in nonmetastatic castration‑resistant prostate cancer (nmCRPC) called DEAR‑EXT,published on Nature, has added new detail to how the three androgen receptor inhibitors (darolutamide, enzalutamide, and apalutamide) behave outside of randomized trials, using data from over 1,300 men treated in US urology practices between 2019 and 2023. The analysis builds on an earlier DEAR study, extending both the number of patients and the follow‑up period to more than two years, while focusing on practical outcomes like how long men stay on treatment, how quickly the disease progresses to metastatic CRPC, how the drugs affect PSA levels, and how safe they appear in everyday practice. Overall, the data suggest that darolutamide may offer a more favorable balance of efficacy and tolerability compared with enzalutamide and apalutamide, even though the study is observational and not a randomized head‑to‑head trial.

Among the 1,375 eligible patients, 565 (41%) started with darolutamide, 609 (44%) with enzalutamide, and 201 (15%) with apalutamide, and baseline characteristics such as age, PSA levels, and Gleason score were broadly similar across groups, which helps reduce concerns that the findings are driven only by strongly different populations. After adjusting statistically for factors like age, race, insurance type, time from nmCRPC diagnosis to treatment, and PSA doubling time, darolutamide was associated with a significantly lower risk of discontinuing the first ARI compared with both enzalutamide and apalutamide, with hazard ratios of 0.73 and 0.69, respectively, translating to roughly a quarter or more reduction in the chance of stopping treatment. The most common reason for stopping was adverse events, with fatigue being the single most frequently reported, and the rate of fatigue‑driven discontinuation was higher in the enzalutamide group than in the darolutamide group. Treatment‑emergent adverse events overall were also somewhat more frequent with enzalutamide and apalutamide than with darolutamide, reinforcing the idea that tolerability may be one of darolutamide’s main advantages in this setting.

In terms of disease control, darolutamide was linked to a lower risk of progression to metastatic castration‑resistant prostate cancer, again compared with both enzalutamide and apalutamide, with hazard ratios around 0.63 and 0.72, indicating about a one‑third to three‑tenths reduction in the risk of moving to metastatic disease over time. Metastasis‑free survival curves separated early, with darolutamide‑treated patients having clearly higher probabilities of remaining metastasis‑free at both 24 and 36 months: for example, estimated metastasis‑free survival at 24 months was about 72% with darolutamide versus just under 60% with enzalutamide and 64% with apalutamide, and at 36 months the darolutamide curve remained higher at above 60% versus the mid‑to‑high 40% range for the other two drugs. The median time to metastasis or death was not reached for darolutamide in these analyses, whereas with enzalutamide and apalutamide it was on the order of the low‑to‑mid 30‑month range, again suggesting that men who start with darolutamide may go longer without developing metastases or dying.

For PSA response, among the subset of men who had baseline PSA above 1.0 ng/mL, darolutamide showed numerically stronger declines than the other two agents. The proportion of patients achieving at least a 50% drop in PSA (PSA50) was about 88% with darolutamide versus mid‑80% levels with enzalutamide and 80% with apalutamide, while the proportion achieving a 90% or greater drop (PSA90) was about 65% with darolutamide versus 64% with enzalutamide and just over 60% with apalutamide. The fraction of patients who reached PSA below 0.2 ng/mL was also slightly higher with darolutamide, which some clinicians interpret as a deeper biochemical response. These PSA patterns are consistent with the phase‑III trials of each drug but now come from a much broader real‑world population, including men with different comorbidities, ages, and prior treatment histories who would not necessarily qualify for controlled studies.

Overall survival, while not the primary endpoint and subject to the usual limitations of observational data, also showed a numerically favorable trend for darolutamide. By 36 months, estimated survival probabilities were about 78% with darolutamide versus 71% with enzalutamide and 74% with apalutamide, again suggesting that staying on effective therapy longer may translate into a survival advantage, even if the study was not designed to prove this with high statistical power. The authors also stress that darolutamide appears to have a lower risk of clinically relevant drug–drug interactions than the other ARIs, because of its distinct pharmacokinetic profile and lower penetration into the brain, which may partly explain why fewer men stop the drug because of side effects and why it may be easier to combine with other medications that older or more complex patients often take. This could matter especially in nmCRPC, where many men are otherwise feeling well but face a high risk of eventual metastatic spread, so the goal is to prevent progression while keeping them on a regimen that they can tolerate for years.

At the same time, the study has important limitations that should not be ignored. Because it is retrospective and observational, there may be unmeasured differences between the groups, such as physicians preferentially choosing darolutamide for frailer or older men, or variations in how often scans or PSA checks were done across different practices.

Source.